

SYNGENTA AG  
Form 6-K  
March 17, 2017

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE  
SECURITIES EXCHANGE ACT OF 1934**

For the month of March, 2017

Commission File Number: 001-15152

**SYNGENTA AG**

(Translation of registrant's name into English)

**Schwarzwaldallee 215**

**4058 Basel**

**Switzerland**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Edgar Filing: SYNGENTA AG - Form 6-K

Form 20-F X Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes NoX

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes NoX

Re: SYNGENTA AG

Disclosure: **“Further expansion of SOLATENOE<sup>TM</sup> fungicide in Europe”**

Herewith we furnish a press release related to Syngenta AG. The full text of the press release is the following:

###

**Syngenta International AG Media contact:**

**Analyst/Investor contact:**

Media Office	Leandro Conti	Jennifer Gough
CH-4002 Basel		+41 61 323
Switzerland	Switzerland +41 61 323 2323	Switzerland 5059
Tel: +41 61 323 2323		USA +1 202 737
Fax: +41 61 323 2424	Paul Minehart	6521
	USA +1 202 737 8913	

[www.syngenta.com](http://www.syngenta.com)

Basel, Switzerland, March 17, 2017

**Further expansion of SOLATENOL™ fungicide in Europe**

**New registration in Germany received**

**Basis for ELATUS™ Era and ELATUS™ Plus fungicides**

**Delivers outstanding control of major cereals diseases**

**First sales in Germany in 2017 season**

Syngenta announced today that the registration of its SDHI fungicide SOLATENOL™ has been further extended in Europe following approval by the German authorities. This most recent registration will allow Syngenta to introduce the products ELATUS™ Era and ELATUS™ Plus to the cereals market in Germany. ELATUS™ Plus is a solo formulation of the active ingredient SOLATENOL™ sold in co-packs with a range of other products. ELATUS™ Era is a combination of the two active ingredients SOLATENOL™ and prothioconazole.

The launch of SOLATENOL™ in Germany for the 2017 season gives growers in another major cereals market access to this leading new technology. SOLATENOL™ is already registered in France, Croatia, UK, Ireland, Finland, Latvia, Estonia and Austria.

SOLATENOL™ is a carboxamide fungicide offering an unrivaled performance against *Septoria* and rusts - two important diseases which can significantly impact cereals production. In trials, it has proven to be extremely consistent in providing excellent disease control on all important cereals varieties in a wide range of situations over several years. The product offers outstanding levels of leaf protection resulting in higher yield and return on investment for the farmer.

SOLATENOL™ is also available for use on soybean in Latin America and on a wide range of crops in the USA and Canada.

### **About Syngenta**

Syngenta is a leading agriculture company helping to improve global food security by enabling millions of farmers to make better use of available resources. Through world class science and innovative crop solutions, our 28,000 people in over 90 countries are working to transform how crops are grown. We are committed to rescuing land from degradation, enhancing biodiversity and revitalizing rural communities. To learn more visit [www.syngenta.com](http://www.syngenta.com) and [www.goodgrowthplan.com](http://www.goodgrowthplan.com). Follow us on Twitter® at [www.twitter.com/Syngenta](https://www.twitter.com/Syngenta).

Syngenta – March 17, 2017 / Page 1 of 2

***Cautionary Statement Regarding Forward-Looking Statements***

This document contains forward-looking statements, which can be identified by terminology such as ‘expect’, ‘would’, ‘will’, ‘potential’, ‘plans’, ‘prospects’, ‘estimated’, ‘aiming’, ‘on track’ and similar expressions. Such statements may be subject to risks and uncertainties that could cause the actual results to differ materially from these statements. We refer you to Syngenta's publicly available filings with the U.S. Securities and Exchange Commission for information about these and other risks and uncertainties. Syngenta assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors. This document does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer, to purchase or subscribe for any ordinary shares in Syngenta AG, or Syngenta ADSs, nor shall it form the basis of, or be relied on in connection with, any contract there for.

Syngenta – March 17, 2017 / Page 2 of 2

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SYNGENTA AG

Date: March 17, 2017 By: /s/ Tobias Meili  
Name: Dr. Tobias Meili  
Title: Head Corporate Legal Affairs

By: /s/ Brigitte Benz  
Name: Brigitte Benz  
Title: Head Shareholder Services & Group Administration